Earnings Call Insights: Profound Medical Corp. (prn:ca) Q1 2026 Management View Rashed Dewan (Chief Financial Officer) said the company “recorded revenue of $5.3 million” in Q1 2026, including “$2.5 million from recurring revenue and $2.9 million from onetime sale of capital equipment,” and reported “gross margin in Q1 2026 was 72%.” Rashed Dewan (Chief Financial Officer) reported operating levera...
Earnings Call Insights: Profound Medical Corp. (prn:ca) Q1 2026 Management View Rashed Dewan (Chief Financial Officer) said the company “recorded revenue of $5.3 million” in Q1 2026, including “$2.5 million from recurring revenue and $2.9 million from onetime sale of capital equipment,” and reported “gross margin in Q1 2026 was 72%.” Rashed Dewan (Chief Financial Officer) reported operating leverage and liquidity, saying “total operating expenses in the 2026 first quarter were $11.8 million,” and “as of March 31, 2026, Profound had cash of $50.3 million.” Dr. Mathieu Burtnyk (President) highlighted the CAPTAIN readout, stating “the CAPTAIN trial demonstrated that TULSA delivered statistically superior quality of life outcomes compared to radical prostatectomy,” including “statistically higher preservation of the composite endpoint of urinary continence and erectile function at 6 months.” Dr. Arun Menawat (Chairman of the Board & CEO) emphasized utilization mix and positioning, saying “about 91% of TULSA patient prostates are treated either as whole gland or more than 50% of prostate ablations,” and framed TULSA as mainstream-capable: “only TULSA has the true potential of becoming a mainstream treatment modality.” Dr. Menawat (Chairman of the Board & CEO) detailed infrastructure and growth indicators, announcing a “new TULSA index table” built from “20 sites” to show “the rate of growth of same-store sales,” and disclosed “the TULSA-PRO installed base was 80 at the end of Q1 2026, and we shipped an additional 6 systems during the first quarter that have yet to be installed.” Dr. Menawat (Chairman of the Board & CEO) tied growth to interventional MRI and partners, saying “the Siemens Free series… is now available and COOK Medical is partnering with them to provide a turnkey iMRI solution,” and added, “we anticipate that if all goes well, TULSA will get FDA clearance for integration with the new interventional MR by year-end.” Outlook Dr. Arun Menawat (Chairman of the ...
North Korea said on Friday it would deploy new long-range artillery systems this year that were capable of striking South Korea’s capital region and would commission its first naval destroyer in coming weeks. The announcement comes days after South Korea said the North’s newly revised constitution drops all references to Korean unification, in line with leader Kim Jong-un’s vows to terminate ties ...
North Korea said on Friday it would deploy new long-range artillery systems this year that were capable of striking South Korea’s capital region and would commission its first naval destroyer in coming weeks. The announcement comes days after South Korea said the North’s newly revised constitution drops all references to Korean unification, in line with leader Kim Jong-un’s vows to terminate ties with South Korea and establish a two-state system on the Korean peninsula. Kim visited a munitions...